Literature DB >> 1551291

Pharmacokinetics of ribostamycin in paediatric patients.

S L Zhou1, G Shen, H F Zhong.   

Abstract

In the present study, ribostamycin concentrations in serum were measured by microbiological assay in 20 paediatric patients aged 3 months to 11 years after intramuscular ribostamycin 10, 15 and 20 mg/kg. All pharmacokinetic parameters and statistical analyses were calculated by computer. These results showed that the absorption rate constant (ka), elimination rate constant (ke), time to peak serum concentration (tmax), elimination half-life (t1/2), apparent volume of distribution (Vd/F), total body clearance (CL) and area under the serum concentration-time curve (AUC) were significantly different in infants under 6 months from those in children over 3 years (p less than 0.05), except for the peak serum concentration (Cmax) and lag time from administration to the first appearance of drug in the serum (tlag) [p greater than 0.05]. The absorption of ribostamycin in infants was more rapid than that in children, but elimination was slower (p less than 0.05). The Vd/F and CL in infants were also larger than in children (p less than 0.01). There were significant positive correlations between Cmax, AUC and ribostamycin dosage (p less than 0.01). Pharmacokinetic parameters for infants and children were compared with those observed in adults, and it was found that ribostamycin absorption and elimination were more rapid in the paediatric patients. The Cmax in children and infants after intramuscular ribostamycin 10 mg/kg approached that in adults after an intramuscular dose of ribostamycin 500mg. Using a 1-compartment open pharmacokinetic model, the optimum intramuscular ribostamycin administration interval was estimated as 6.01 and 7.56h for children and infants, respectively, while the value was 8.5h in adults. When the drug was administered in multiple doses of 15 mg/kg intramuscularly every 8h, no accumulation occurred in children. It is suggested that ribostamycin be administered in intramuscular doses of 10 to 15 mg/kg twice daily in infants and 3 times daily in children, respectively.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1551291     DOI: 10.2165/00003088-199222020-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  12 in total

1.  Blood flow in muscle groups and drug absorption.

Authors:  E F Evans; J D Proctor; M J Fratkin; J Velandia; A J Wasserman
Journal:  Clin Pharmacol Ther       Date:  1975-01       Impact factor: 6.875

2.  [A non-linear method and its program for calculating pharmacokinetic parameters].

Authors:  Y C Yang; G Chen; L Yuan
Journal:  Zhongguo Yao Li Xue Bao       Date:  1983-12

Review 3.  Clinical pharmacokinetics in newborns and infants. Age-related differences and therapeutic implications.

Authors:  P L Morselli; R Franco-Morselli; L Bossi
Journal:  Clin Pharmacokinet       Date:  1980 Nov-Dec       Impact factor: 6.447

4.  Comparative antimicrobial activities of ribostamycin, gentamicin, ampicillin and lincomycin in vitro and in vivo.

Authors:  S Inouye; T Watanabe; I Kitasato
Journal:  Drugs Exp Clin Res       Date:  1989

5.  Comparative nephrotoxicity of ribostamycin and gentamicin in rats evaluated by urinalysis.

Authors:  I Kitasato; T Niizato; S Inouye
Journal:  Drugs Exp Clin Res       Date:  1989

6.  Postconceptional age and gentamicin elimination half-life.

Authors:  J W Kasik; S Jenkins; M P Leuschen; R M Nelson
Journal:  J Pediatr       Date:  1985-03       Impact factor: 4.406

7.  Age-associated changes in ceftriaxone pharmacokinetics.

Authors:  W L Hayton; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

8.  Estimation of gentamicin clearance and volume of distribution in neonates and young children.

Authors:  A W Kelman; A H Thomson; B Whiting; S M Bryson; D A Steedman; G E Mawer; L A Samba-Donga
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

9.  Comparative study by scanning electron microscopy on vestibular toxicities of dibekacin, ribostamycin, and other aminoglycoside antibiotics in guinea pigs.

Authors:  K Sato; T Saito; T Matsuhira
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1983-03

Review 10.  Clinical pharmacokinetics in infants and children. A reappraisal.

Authors:  G L Kearns; M D Reed
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

View more
  1 in total

1.  Targeting the nsp2 Cysteine Protease of Chikungunya Virus Using FDA Approved Library and Selected Cysteine Protease Inhibitors.

Authors:  Prateek Kumar; Deepak Kumar; Rajanish Giri
Journal:  Pathogens       Date:  2019-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.